Top Markets
#1 Pleasing Gold Pleasing Gold +1,510.61%
#2 Ontology Gas Ontology Gas +96.40%
#3 PulseChain PulseChain +61.85%
#4 Osmosis Osmosis +33.22%
#5 BOOK OF MEME BOOK OF MEME +32.36%
#6 Neiro Neiro +30.17%
#7 Collect on Fanable Collect on Fanable +29.35%
#8 Unit Pump Unit Pump +28.42%
#9 Pump.fun Pump.fun +28.42%
#10 Ontology Ontology +25.90%
Coin of the day
Pleasing Gold Pleasing Gold
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Rang in aandelen #25854
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Aandeelprijs
$15.31
Laatst gesynchroniseerd: 2024-02-29
Marktkapitalisatie
$45.70M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Icosavax, Inc. (ICVX)

Categorie

Healthcare
Winst voor Icosavax, Inc. (ICVX)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Icosavax, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Icosavax, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US